A 67-year-old woman with type 2 diabetes and NASH experienced significant clinical and histological improvements in liver function after four months of treatment with the SGLT2 inhibitor ipragliflozin, including normalized ALT and ferritin levels, reduced fibrosis markers, decreased liver fat, and improved steatosis, inflammation, and ballooning [241]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.